申请人:Evans Gary Brian
公开号:US20100168141A1
公开(公告)日:2010-07-01
Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH
2
OH, CH
2
OQ and CH
2
SQ; Y and Z are each independently selected from hydrogen, halogen, CH
2
OH, CH
2
OQ, CH
2
SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R
1
is a radical of the formula (II) or R
1
is a radical of the formula (III) A is selected from N, CH and CR
2
, where R
2
is selected from halogen, alkyl, aralkyl, aryl, OH, NH
2
, NHR
3
, NR
3
R
4
and SR
5
, where R
3
, R
4
and R
5
are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R
2
is optionally substituted with hydroxy or halogen when R
2
is alkyl, aralkyl or aryl; B is selected from hydroxy, NH
2
, NHR
6
, SH, hydrogen and halogen, where R
6
is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH
2
, NHR
7
, hydrogen, halogen and SCH
3
, where R
7
is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C
1-4
saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.
具有通式(I)的核苷酸酶和核苷酸磷酸酶抑制剂的氮杂环类似物,以这些化合物作为药物,含有这些化合物的制药组合物,使用这些化合物治疗某些疾病的方法,制备这些化合物的方法,以及制备这些化合物有用的中间体,其中W和X各自独立地选自氢,CH2OH,CH2OQ和CH2SQ; Y和Z各自独立地选自氢,卤素,CH2OH,CH2OQ,CH2SQ,SQ,OQ和Q; Q是一种烷基,芳基或芳基烷基,每个基团可以选择性地取代一个或多个亲水基,卤素,甲氧基,氨基或羧基; R1是公式(II)的基团或R1是公式(III)的基团,其中A选自N,CH和CR2,其中R2选自卤素,烷基,芳基烷基,芳基,OH,NH2,NHR3,NR3R4和SR5,其中R3,R4和R5均为烷基,芳基烷基或芳基,可以选择性地取代亲水基或卤素,当R2为烷基,芳基烷基或芳基时,R2可以选择性地取代亲水基或卤素; B选自羟基,NH2,NHR6,SH,氢和卤素,其中R6是烷基,芳基烷基或芳基,可以选择性地取代亲水基或卤素; D选自羟基,NH2,NHR7,氢,卤素和SCH3,其中R7是烷基,芳基烷基或芳基,可以选择性地取代亲水基或卤素; E选自N和CH; G是C1-4饱和或不饱和烷基,可以选择性地取代亲水基或卤素,或者G不存在; 或其互变异构体,或其药学上可接受的盐,或其酯,或其前药。